



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



PRODUCT INFORMATION

Clone ID	DM22
Target	Nucleocapsid
Synonyms	SARS-CoV-2 Nucleocapsid
Host Species	Rabbit
Description	PE-conjugated Anti-SARS-CoV-2 Nucleocapsid antibody(DM22); Rabbit mAb
Delivery	Under Development
Uniprot ID	P0DTC9
IgG type	Rabbit IgG
Clonality	Monoclonal
Reactivity	SARS-CoV-2
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Liquid□PBS with 0.05% Proclin300, 1% BSA
Storage & Shipping	Store at 2°C-8°C for 6 months
Background	Coronavirus contain most of nucleocapsid protein. Coronavirus nucleoproteins (N proteins) localize to the cytoplasm and the nucleolus; a subnuclear structure; in both virus-infected primary cells and in cells transfected with plasmids that express N protein. The nucleolus is the site of ribosome biogenesis and sequesters cell cycle regulatory complexes. Two of the major components of the nucleolus are fibrillarin and nucleolin. These proteins are involved in nucleolar assembly and ribosome biogenesis and act as chaperones for the import of proteins into the nucleolus. Regarding of the conservation of N protein sequence and its strong immunogenicity; the N protein of coronavirus is a tool for diagnostic.
Usage	Research use only
Conjugate	PE-conjugated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

